CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Heart Failure and Atrial Fibrillation, Like Fire and Fury Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Dilated cardiomyopathy: so many cardiomyopathies! Primary Prevention of Heart Failure in Women Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction

Clinical TrialFebruary 6, 2018, Volume 137, Issue 6

JOURNAL:Circulation Article Link

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study

M .Kosiborod, CVD-REAL Investigators and Study Group. Keywords: SGLT2 inhibitor; death; diabetes mellitus; heart failure; observational studies

FULL TEXT PDF